We could not find any results for:
Make sure your spelling is correct or try broadening your search.
IN8bio Inc is a clinical-stage biotechnology company. It is focused on developing innovative therapies for the treatment of cancers, including solid tumors, by employing allogeneic, autologous and genetically modified gamma-delta T cells. IN8bio Inc is a clinical-stage biotechnology company. It is focused on developing innovative therapies for the treatment of cancers, including solid tumors, by employing allogeneic, autologous and genetically modified gamma-delta T cells.
NEW YORK, May 24, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB) a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced multiple...
NEW YORK, May 23, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB) a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced an upcoming...
NEW YORK, May 14, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc.Β (Nasdaq: INAB) a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, announced today a...
NEW YORK, May 13, 2024 (GLOBE NEWSWIRE) -- IN8bio (Nasdaq: INAB), a clinical-stage biopharmaceutical company advancing innovative gamma-delta T cell therapies, presented in an oral session...
- Presented new preclinical data demonstrating proof-of-concept for non-signaling Chimeric Antigen Receptor (nsCAR) platform to effectively target cancer cells while preserving healthy tissue...
NEW YORK, April 30, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company advancing innovative gamma-delta T cell therapies, announced today that the...
NEW YORK, April 24, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc.Β (Nasdaq: INAB) a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced an oral...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.17 | 16.1904761905 | 1.05 | 1.28 | 0.995 | 67117 | 1.02552593 | CS |
4 | 0.17 | 16.1904761905 | 1.05 | 1.28 | 0.9734 | 116522 | 1.0583914 | CS |
12 | -0.02 | -1.61290322581 | 1.24 | 1.45 | 0.9164 | 322801 | 1.10735888 | CS |
26 | 0.354 | 40.8775981524 | 0.866 | 2.48 | 0.79051 | 474726 | 1.41237707 | CS |
52 | -1.66 | -57.6388888889 | 2.88 | 3.21 | 0.65 | 314624 | 1.42965201 | CS |
156 | -8.78 | -87.8 | 10 | 10.319 | 0.65 | 581489 | 2.52589782 | CS |
260 | -8.78 | -87.8 | 10 | 10.319 | 0.65 | 581489 | 2.52589782 | CS |
Symbol | Price | Vol. |
---|---|---|
NVOSNovo Integrated Sciences Inc | $ 1.05 (132.82%) | 310.28M |
GWAVGreenwave Technology Solutions Inc | $ 0.0387 (-7.86%) | 305.13M |
FFIEFaraday Future Intelligent Electric Inc | $ 0.584899 (3.47%) | 223.84M |
SQQQProShares UltraPro Short QQQ | $ 10.02 (0.00%) | 161.89M |
CRKNCrown Electrokinetics Corporation | $ 0.0998 (-12.07%) | 155.13M |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions